Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25937220 | 1.00 | CYP19A1 (0.33) | CYP19A1 | |
| SCHEMBL2580348 | 0.87 | ACHE (0.34) | — | |
| SCHEMBL2580352 | 0.87 | ACHE (0.34) | — | |
| SCHEMBL2580350 | 0.87 | ACHE (0.34) | — | |
| SCHEMBL5639385 | 0.86 | CA1 (0.34) | — | |
| SCHEMBL6135269 | 0.86 | CA1 (0.34) | — | |
| SCHEMBL6132278 | 0.86 | CA1 (0.34) | — | |
| SCHEMBL14779612 | 0.85 | USP2 (0.33) | — | |
| SCHEMBL18591915 | 0.83 | USP2 (0.32) | — | |
| SCHEMBL18591924 | 0.83 | USP2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108697714-B | Fused pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2022-04-26 | — | — | CN | disclosed |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11008324-B2 | — | — | 2021-05-18 | — | — | US | disclosed |
| US-10807986-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-10-20 | — | — | US | disclosed |
| US-20200270253-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-08-27 | — | — | US | disclosed |
| US-20190330214-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2019-10-31 | — | — | US | disclosed |
| US-10155768-B2 | Fused pyrimidine compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-12-18 | — | — | US | disclosed |
| CN-108697714-A | Novel fused pyrimidine compound or its salt | 大鹏药品工业株式会社 | 2018-10-23 | — | — | CN | disclosed |
| EP-3269370-A1 | NOVEL CONDENSED PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-01-17 | — | — | EP | disclosed |
| US-20180009818-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-11 | — | — | US | disclosed |
| CN-103180322-A | Pyrazole compounds as jak inhibitors | CELLZOME LTD | 2013-06-26 | — | — | CN | disclosed |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| EP-2566867-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2013-03-13 | — | — | EP | disclosed |
| WO-2011134831-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| US-20110184000-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | REGAN FOUNDATION (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | REGAN FOUNDATION (BE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | REGAN FOUNDATION (BE) | 2007-08-16 | — | — | US | disclosed |
| EP-1622913-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096813-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330214-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | CYP19A1 3057/4885 |
| US-20180009818-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | CYP19A1 3057/4885 |
| US-20110184000-A1 | 1-HETEROCYCLYL-1,5-DIHYDRO-PYRAZOLO[3,4-D] PYRIMIDIN-4-ONE DERIVATES AND THEIR USE AS PDE9A MODULATORS | PDE9A, PDE7A, PDE1A | CYP19A1 890/4885 |
| US-11046696-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | CYP19A1 2580/4885 |
| US-11008324-B2 | — | RET, GFRA1, GFRA2 | CYP19A1 1911/4885 |
| US-10155768-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | CYP19A1 2580/4885 |
| US-20070191373-A1 | Heterocyclic compounds for use in the treatment of viral infections | TPMT, TYMP, HAVCR2 | CYP19A1 4498/4885 |
| US-10807986-B2 | Fused pyrimidine compound or salt thereof | RET, ZFX, MECP2 | CYP19A1 2580/4885 |
| US-20200270253-A1 | NOVEL FUSED PYRIMIDINE COMPOUND OR SALT THEREOF | RET, ZFX, PDCD11 | CYP19A1 3057/4885 |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK3, JAK2 | CYP19A1 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.